转移性前列腺癌中基于镥-177和锕-225的前列腺特异性膜抗原放射性配体治疗的疗效、毒性和生活质量结局的荟萃分析与荟萃回归
该系统评价与荟萃分析纳入100项研究共8711例转移性前列腺癌患者,评估[177Lu]Lu-PSMA和[225Ac]Ac-PSMA放射性配体治疗的疗效、安全性和生活质量。PSA下降≥50%的估计比例在[177Lu]Lu-PSMA为0.49、[225Ac]Ac-PSMA为0.60,累积给药活度与PSA≥50%下降比例相关,[177Lu]Lu-PSMA后生活质量改善,严重毒性不常见。
要点
- PSA下降≥50%的估计比例:[177Lu]Lu-PSMA为0.49,[225Ac]Ac-PSMA为0.60。
- 荟萃回归提示累积给药活度与PSA≥50%下降比例相关。
- [177Lu]Lu-PSMA后生活质量改善,[225Ac]Ac-PSMA第二周期后保持稳定。
核心结论
- 研究结果提示PRLT与转移性前列腺癌中PSA水平下降及生存结局改善相关。
- 分析显示该治疗相关的严重毒性发生率低。
- 这些观察凸显了PRLT在转移性前列腺癌管理中的重要作用。
研究设计与样本
- 系统评价、荟萃分析与荟萃回归,检索PubMed/Medline、EMBASE、Web of Science、Scopus和Cochrane Library。
- 共纳入100项研究、8711例患者。
- 分析PSA应答、毒性特征、生活质量与生存结局,采用比例荟萃分析和荟萃回归分析。
主要发现
- 在转移性前列腺癌尤其转移性去势抵抗性前列腺癌中,PSA下降≥50%的估计比例[177Lu]Lu-PSMA为0.49、[225Ac]Ac-PSMA为0.60。
- 荟萃回归分析提示累积给药活度与PSA≥50%下降比例之间存在关联。
- 两种治疗中均观察到PSA阳性应答伴随总生存改善。
- 分析识别了与PSA应答和生存结局相关的关键因素,包括基线血红蛋白水平和内脏转移的存在。
- [177Lu]Lu-PSMA治疗中贫血常见但严重毒性不常见;[177Lu]Lu-PSMA后生活质量改善,而[225Ac]Ac-PSMA第二周期治疗后生活质量保持稳定。
局限性
- 研究间PSA应答和毒性特征的异质性是一项局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Management of metastatic prostate cancer (mPCa) presents significant challenges. In this systematic review, meta-analysis, and meta-regression, the efficacy, safety, and quality of life (QoL) outcomes of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) utilising lutetium-177 ([177Lu]Lu-PSMA) and actinium-225 ([225Ac]Ac-PSMA) were assessed. METHODS: A detailed literature search across PubMed/Medline, EMBASE, Web of Science, Scopus, and Cochrane Library was conducted, culminating in the inclusion of 100 studies involving 8711 patients. Data on prostate-specific antigen (PSA) responses, toxicity profiles, and QoL and survival outcomes were analysed. Proportional meta-analyses and meta-regression analyses were performed. KEY FINDINGS AND LIMITATIONS: The estimated proportion of patients with PSA decline ≥50% was 0.49 for [177Lu]Lu-PSMA and 0.60 for [225Ac]Ac-PSMA in mPCa, particularly metastatic castration-resistant prostate cancer. A meta-regression analysis indicated an association between the cumulative amount of administered activity and the proportion of PSA ≥50% decline. Positive PSA responses were observed alongside improved overall survival across both therapies. Our analyses also identified the key factors associated with PSA responses and survival outcomes, including baseline haemoglobin level, and the presence of visceral metastases. Although anaemia was commonly observed, with [177Lu]Lu-PSMA, severe toxicities were infrequent. Improved QoL was observed following [177Lu]Lu-PSMA therapy, whereas it remained stable following the second cycle of [225Ac]Ac-PSMA treatment. Heterogeneity across studies for PSA responses and toxicity profiles is a limitation. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our findings suggest an association between PRLT and reductions in PSA levels, as well as associations with enhanced survival outcomes in mPCa. Furthermore, our analysis shows a low incidence of severe toxicity associated with this treatment. These observations highlight the important role of PRLT in the management of mPCa.
引用
- Dai YH, Chen PH, Lee DJ, et al. A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer. Eur Urol. 2024. PMID: 39327114. doi:10.1016/j.eururo.2024.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。